Dr Colin Hayward, Telix Chief Medical Officer, said, “Building on the success of ZIRCON and positive
preliminary results in investigator-initiated studies of TLX250-CDx in bladder and breast cancer,
4 dosing a first patient in the STARBURST study is a strategically important milestone for Telix. This
study will add value and clinical insight to the platform and enable Telix to assess the potential of
CAIX as a biomarker as we continue to scout the theranostic potential of targeting CAIX beyond
renal cancer. We would like to thank Dr Kiser and his clinical team at Carilion Clinic, as well as the
patients who will contribute to the study.”
Another positive step for Telix.
- Forums
- ASX - By Stock
- Ann: Phase II study for indication expansion of TLX250-CDx doses
Dr Colin Hayward, Telix Chief Medical Officer, said, “Building...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$17.55 |
Change
-0.450(2.50%) |
Mkt cap ! $5.872B |
Open | High | Low | Value | Volume |
$17.90 | $17.95 | $17.42 | $21.96M | 1.248M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 17117 | $17.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.57 | 2880 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9791 | 17.540 |
1 | 3048 | 17.510 |
1 | 500 | 17.500 |
1 | 50 | 17.470 |
1 | 20 | 17.460 |
Price($) | Vol. | No. |
---|---|---|
17.570 | 2880 | 1 |
17.600 | 4130 | 2 |
17.620 | 2880 | 1 |
17.650 | 2880 | 2 |
17.660 | 2571 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online